All In Biotech

Drug Trial Radar · NCT06173570

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia

A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants With Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

428

Actual

Start

Jan 19, 2024

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.

Conditions

  • Dyslipidemia

Interventions

  • AZD0780Drug

    AZD0780 administered orally, once daily for 12 weeks

  • PlaceboDrug

    Placebo administered orally, once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12Time frame: From first day of treatment up to week 12

Locations

55 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Lincoln, California

  • Research Site

    Palm Springs, California

  • Research Site

    Santa Ana, California

  • Research Site

    Boca Raton, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Inverness, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Windsor, New York

  • Research Site

    Greensboro, North Carolina

  • Research Site

    Fargo, North Dakota

  • Research Site

    San Marcos, Texas

  • Research Site

    Barrie, Ontario, Canada

  • Research Site

    Brampton, Ontario, Canada

  • Research Site

    Cambridge, Ontario, Canada

  • Research Site

    Concord, Ontario, Canada

  • Research Site

    Guelph, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Benešov, Czechia

  • Research Site

    Brandýs nad Labem, Czechia

  • Research Site

    Brno, Czechia

  • Research Site

    Louny, Czechia

  • Research Site

    Náchod, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Příbram, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Uherské Hradiště, Czechia

  • Research Site

    Aarhus, Denmark

  • Research Site

    Herning, Denmark

  • Research Site

    Hvidovre, Denmark

  • Research Site

    Svendborg, Denmark

  • Research Site

    Viborg, Denmark

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Orosháza, Hungary

  • Research Site

    Pécs, Hungary

  • Research Site

    Chūōku, Japan

  • Research Site

    tabashi City, Japan

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.